Tobacco Dependence Clinical Trial
— EUREST-PLUSOfficial title:
European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Diseases (EUREST-PLUS)
NCT number | NCT02773836 |
Other study ID # | 681109 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 15, 2016 |
Est. completion date | May 6, 2018 |
Verified date | February 2019 |
Source | European Network For Smoking and Tobacco Prevention |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The main objective of EUREST-PLUS is to monitor and evaluate the impact of the Tobacco
Products Directive (TPD) within the context of FCTC ratification at an EU level. The
investigators specific objectives, within WorkPackage 2 and Workpackage 3 are: To evaluate
the psychosocial and behavioral impact of TPD implementation and FCTC implementation, through
the creation of a cohort study of adult smokers in 6 European Member States (EU MS), Germany,
Greece, Hungary, Poland, Romania, Spain; (total n=6000) in a pre- vs. post-TPD study design.
EUREST-PLUS is funded through the European Union's Horizon 2020 research and innovation
programme under grant agreement No 681109
Status | Completed |
Enrollment | 6036 |
Est. completion date | May 6, 2018 |
Est. primary completion date | September 12, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be 18 years of age or older. - Must smoke at least monthly. - Must have smoked 100 cigarettes in their lifetime. - Must live in the household visited Exclusion Criteria: - Inability to complete the questionnaire due to health/mental incapability. - Unable to provide consent to participate. |
Country | Name | City | State |
---|---|---|---|
Belgium | European Network For Smoking and Tobacco Prevention | Brussels |
Lead Sponsor | Collaborator |
---|---|
European Network For Smoking and Tobacco Prevention | AER PUR ROMANIA, DOHANYZAS VAGY EGESZSEG MAGYAR ALAPITVANY, European Respiratory Society, German Cancer Research Center, Institut Català d'Oncologia, King's College London, Maastricht University, PROMOCJA ZDROWIA - ZDROWIE ALBO TYTON FUNDACJA, TNS OPINION SA, University of Athens, University of Crete, University of Waterloo |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Think About the Harm of Smoking | In the last 30 days, how often did you think about the harm your smoking might be doing to you? responses: Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Baseline Pre-TPD | |
Primary | Number of Participants Whose First Cigarette After Waking is 30 Mins or Less | How soon after waking do you usually have your first smoke? responses: 5 min or less 6-30 min 31-60 min More than 60 min |
Baseline Pre-TPD | |
Primary | Number of Participants Who Think About How Much They Enjoy Smoking by Frequency | The following question ask you about how often you've had certain thoughts in the last 30 days. In the last 30 days, how often did you . . . Think about how much you enjoy smoking? Never Rarely Sometimes Often Very often Refused Don't know |
Baseline Pre-TPD | |
Primary | Number of Participants Who Have Ever Tried to Quit Smoking | Have you ever tried to quit smoking? Yes No 8 Refused 9 Don't know |
Baseline Pre-TPD | |
Primary | Number of Participants Who Plan to Quit Smoking | Are you planning to quit smoking . . . Within the next month Within the next 6 months Sometime in the future, beyond 6 months Or are you not planning to quit? 8 Refused 9 Don't know |
Baseline Pre-TPD | |
Primary | Number of Participants Who Think About the Harm of Smoking | In the last 30 days, how often did you think about the harm your smoking might be doing to you? responses: Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Post-TPD | |
Primary | Number of Participants Whose First Cigarette After Waking is 30 Mins or Less | How soon after waking do you usually have your first smoke? responses: 5 min or less 6-30 min 31-60 min More than 60 min |
Post-TPD | |
Primary | Number of Participants Who Have Ever Tried to Quit Smoking | Have you ever tried to quit smoking? Yes No 8 Refused 9 Don't know |
Post-TPD | |
Primary | Number of Participants Who Plan to Quit Smoking | Are you planning to quit smoking . . . Within the next month Within the next 6 months Sometime in the future, beyond 6 months Or are you not planning to quit? 8 Refused 9 Don't know |
Post-TPD | |
Secondary | Number of Participants Who Think About The Money They Spend on Smoking | The following question ask you about how often you've had certain thoughts in the last 30 days. In the last 30 days, how often did you Think about the money you spend on smoking? Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Baseline Pre-TPD | |
Secondary | Number of Participants Who Think About the Harm Their Smoking Might be Doing to Other People | The following question ask you about how often you've had certain thoughts in the last 30 days. In the last 30 days, how often did you Think about the harm your smoking might be doing to other people? Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Baseline Pre-TPD | |
Secondary | Number of Participants Who Think About The Money They Spend on Smoking | The following question ask you about how often you've had certain thoughts in the last 30 days. In the last 30 days, how often did you Think about the money you spend on smoking? Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Post-TPD | |
Secondary | Number of Participants Who Think About the Harm Their Smoking Might be Doing to Other People | The following question ask you about how often you've had certain thoughts in the last 30 days. In the last 30 days, how often did you Think about the harm your smoking might be doing to other people? Never Rarely Sometimes Often Very often 8 Refused 9 Don't know |
Post-TPD |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
Completed |
NCT00747643 -
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|
N/A | |
Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A |